Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

Blood - 15 Apr 2006

Jones Amy V, Silver Richard T, Waghorn Katherine, Curtis Claire, Kreil Sebastian, Zoi Katerina, Hochhaus Andreas, Oscier David, Metzgeroth Georgia, Lengfelder Eva, Reiter Andreas, Chase Andrew J, Cross Nicholas C P

Abstract excerpt

Imatinib and recombinant interferon alpha (rIFNalpha) can induce remission in polycythemia vera (PV) patients, but gauging the depth of responses has not been possible due to lack of a specific disease marker. We found that patients undergoing imatinib (n = 14) or rIFNalpha (n = 7) therapy remain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Hematopoiesis
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon Type I

Share to Janus Kinase 2

Share to Piperazines

Share to Polycythemia Vera

Share to Remission Induction

Source

Identifiers

PMID: 16352805
DOI: 10.1182/blood-2005-09-3917

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16352805-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.PMID 16352805Read ↗

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.Semantic proximity Read ↗

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.Semantic proximity Read ↗

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alphaSemantic proximity Read ↗

Imatinib effect on growth and signal transduction in polycythemia vera.Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.Semantic proximity Read ↗

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia veraSemantic proximity Read ↗

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Semantic proximity Read ↗

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoSemantic proximity Read ↗

Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.